glp-1 medications mechanism of action Receptor Agonists as Treatments for Type 2 Diabetes Science Behind GLP 1 GIP

Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index

it provides valuable data that informs dose titration, identifies adverse effects early, and ultimately improves treatment adherence and clinical outcomes

Structural insights into the T6SS effector protein Tse3 and the Tse3-Tsi3 complex from Pseudomonas aeruginosa reveal a calcium-dependent membrane-binding mechanism

Dwight et al., 2013

Rather than supplying synthetic growth hormone directly, these peptides are studied for their ability to interact with receptors involved in natural growth hormone secretion patterns